Radiopharmaceutical Tektrotyd continues to receive interest and recognition

Published on November 8, 2012 at 3:51 AM · No Comments

Physicians - attendees of the 25th Annual EANM (European Association of Nuclear Medicine) Congress (October 27-31, Milan) - expressed their continuing interest in and recognition for Tektrotyd, a radiopharmaceutical responsible for significant progress in diagnostics/therapy of neuroendocrine tumours.

Tektrotyd kits containing 99mTc radioisotope have been manufactured in NCBJ POLATOM Radioisotopes Centre in Świerk since 2005. They are highly valued in treatment of neuroendocrine tumours since they increase efficacy of therapy of these difficult to cure cancer types. These peculiar cancers develop on endocrine cells dispersed all over the human body. Majority of the tumours locate themselves within alimentary canal and/or in pancreas. As soon as 10 minutes after intravenous injection of Tektotryd, 99mTc starts to accumulate in cancer cells. The best images of tumours may be observed between 2nd and 4th hour of the test. The test is particularly useful in case of inactive neuroendocrine tumours that do not manifest themselves with any clinical symptoms. In the past such tumours were usually undiagnosed until a very late phase when they were already accompanied by numerous metastases. The injected radioisotope is soon excreted from the patient body with urine, giving no side effects. The procedure is relatively simple and patients may be administered the radioisotope without any need to stay in hospital.

„Synthetic eight-amino-acid Tyr3-octreotide peptide is an active substance in the medicine developed by us. A nicotinic acid hydrazide molecule bound to the peptide makes possible to label the substance with the 99mTc (technetium) radioisotope"-explains Dr. Renata Mikołajczak, NCBJ POLATOM Director Proxy - „Since cancer cells of neuroendocrine tumours exhibit an increased expression of somatostatin receptors, the active substance preferentially binds with them. Radiation emitted by decaying atoms of the technetium-99m label is detected to precisely localize the tumour and its metastases. Such images help physicians to assess how extensive the neoplasm processes are and to optimize treatment of the patient".

Technetium-99m is produced in 99Mo/99mTc radionuclide generators in decays of atoms of the molybdenum-99 isotope. The latter is produced by means of a multi-stage processing of uranium-235 containing targets irradiated in research reactors such as the MARIA reactor operated in NCBJ. In Świerk the uranium targets are irradiated in some specially designed reactor channels.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment